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As the COVID-19 pandemic exacts its toll with escalating morbidity 
and mortality in most major regions of the world,[1] the African 
continent waits in line to receive its share of viral mayhem. Despite 
prompt state action in which the South African (SA) National 
Department of Health (NDoH) invoked the Disaster Management 
Act 57 of 2002,[2] allowing several extraordinary containment 
measures to limit the spread of disease, the country may soon 
experience the worst public health crisis in its history. Researchers, 
clinicians, front-line health workers, captains of industry, politicians 
and civil society have rallied together to seek solutions intended to 
minimise illness and death.
Ethics deliberations during the early phase of the pandemic have 
focused on fair allocation of scarce resources – mainly beds in 
intensive care units (ICUs) with or without invasive ventilation.[3-7] 
While mechanical ventilation forms an integral part of international 
treatment guidelines[8] for the clinical management of COVID-19-
related severe acute respiratory infection, it appears that traditional 
ventilation protocols may not benefit, and indeed may be harmful to, 
some mechanically ventilated patients.[9] Given the unexpected and 
unusual clinical expression of pulmonary disease in many patients 
presenting to critical care units, scientific research to guide clinical 
decision-making has become imperative.[10] Although COVID-19 
mortality is high in patients admitted to ICUs, autopsies are not being 
routinely conducted globally given the high associated risk, especially 
in contexts with severe shortages of personal protective equipment 
(PPE) and lack of biosafety-approved mortuary facilities.[11,12] It is the 
exception rather than the rule to see data of full autopsies to establish 
cause of death during this pandemic.[10,13-15] SA is no exception, with 
no published autopsy pathology data currently available.
A compromise could be collection of samples of lung tissue 
immediately after death in ICU settings to better understand the 
underlying pathology.[16,17] Scientific data collected in this manner 
could provide clues to the pathogenesis of mortality and thereby 
assist in the clinical management of future patients.[18] An argument 
for this type of research being in the public interest can hence be 
justified.
Pandemics or humanitarian crises challenge clinicians and 
scientists in many ways, especially when the virus is novel and 
disease expression becomes variable or unpredictable. Under such 
circumstances, research becomes critical to inform clinical care. [19-21] 
Despite this compelling research imperative, it is important that 
medical care and service delivery must always take precedence 
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over research,[22] especially if the crisis worsens. In resource-limited 
settings, research is often conducted by the same people who provide 
care and therefore ‘rightly takes second place to the provision of life-
saving assistance’.[23] In contrast, in resource-rich environments, there 
may be specific personnel assigned exclusively to research, so that 
critical human resources would not be diverted away from care.[24]
Assuming that there is both sufficient staff and time for research 
and care in SA and that all researchers involved in the project 
have PPE and training, this type of critical care research would 
be invaluable to inform the optimal management of the severe 
respiratory complications resulting from COVID-19. The research 
team would need to develop a detailed standard operating procedure 
to ensure efficient conduct of the planned research project, even in 
a busy ICU setting. The ethical conduct of research under normal 
circumstances would include obtaining voluntary informed consent 
unless unique circumstances make this impractical, impossible or 
even unethical.[25]
ICU research often precludes a  
regular consent process
Conducting research on critically ill patients in an emergency room 
or ICU is not unprecedented and is possibly most needed due to 
inherent high mortality rates in this domain. Several important 
studies yielding important clinical data that have shaped and guided 
critical care practice have been conducted globally over many 
decades.[26-29] In anticipation, international research ethics guidance 
has made provision for such research, albeit usually in a living patient 
under relatively calmer circumstances.[30,31] SA is no exception. 
The 2015 guidance issued by the NDoH, Ethics in Health Research: 
Principles, Processes and Structures,[32] specifies in section 3.4.2 that 
ICU research may be characterised by communication challenges 
either due to ventilation or to cognitive impairment as a result 
of sedation. Under these circumstances, and ‘wherever possible’, 
consent for ‘planned intensive care research should be obtained from 
potential participants before admission to that care’. Should this not 
be possible, in ‘particular circumstances, the REC [research ethics 
committee] may approve delayed consent. Note this does not mean 
that informed consent is waived.’ According to the guideline,[32] a 
delay in obtaining informed consent may be approved if: 
• the research is based on valid scientific hypotheses that support 
a reasonable possibility of more benefit than that offered by 
standard care
• participation is not contrary to the medical interests of the patient
• the research interventions pose no more risk of harm than that 
inherent in the patient’s condition or alternative methods of 
treatment
• as soon as reasonably possible, the participant and his/her relatives 
or legal representatives will be informed of the participant’s 
inclusion in the research, be requested to give delayed consent, and 
be advised of the right to withdraw from the research without any 
reduction in quality of care. This clearly applies to a living person.
Guidance on research during 
pandemics
Although the national guidance[32] does not refer to pandemics 
directly, they are included in section 3.4.1 as ‘major incidents’ 
and include ‘any sudden event that occurs where local resources 
are constrained, so that responding urgently and appropriately is 
difficult’, including in the context of outbreaks of deadly disease. 
A major incident ‘may take the form of an unusual and sudden 
demand on local resources or other emergency with consequent 
ethical implications for patient care’. In such contexts, research would 
be ‘important for advancing emergency health care interventions 
and treatments, and for refining resource allocation policies’. The 
potential benefits of major incident research include ‘improved triage 
methods and procedures, effective treatment for life-threatening 
conditions and improving therapies for survival and quality of life’. 
Despite the extreme vulnerability of patients in such contexts, the 
guidance advises that RECs should be ‘cautious about being overly 
restrictive about the type of research that may be conducted’. This 
is complicated by the fact that proposals for major incident research 
usually demand expedited processing, which would reduce the time 
available for thoughtful deliberation by the REC. It is acknowledged 
that informed consent will have to be obtained quite rapidly and 
at a time when ‘vulnerability of patients and families is likely to be 
extreme’. Patients may be incapacitated (i.e. unconscious or on a 
ventilator), which points to the likelihood of difficulties with the 
usual approach to informed consent. Consequently, RECs may 
consider ‘alternative approaches such as proxy consent or delaying 
consent in particular circumstances’. Here too the guidance applies 
to living patients and families, although their extreme vulnerability 
is acknowledged.
Surrogate decision-makers or proxy 
consent for persons who lack capacity
In section 3.2.4.3 of the national research ethics document,[32] 
guidance is provided for the conduct of research in adults incapable 
of giving adequate informed consent. The guidance highlights the 
legal position in SA where ‘proxy decision makers are not permitted 
for adult persons who lack capacity unless the proxy is a court-
appointed curator’. While the National Health Act 61 of 2003 and 
the Mental Health Care Act 17 of 2002 make provision for proxy 
decision-makers for treatment, they do not refer to proxy decision-
making for research. However, since the guidance argues that it 
would be ‘unethical to exclude a category of persons from research 
participation without adequate justification’, an ethical argument 
could be made for using the statutory treatment proxies to provide 
permission for participation in research that complies with specific 
stipulations. In unusual circumstances, e.g. major incident research 
(see section 3.4.1), it may be ethically acceptable to permit proxy 
consent also in a situation where no statutory proxy is available 
but the ratio of risk of harm to knowledge justifies it. In particular 
circumstances, the REC may approve delayed consent. Again, the 
guidance cautions that this does not mean that informed consent is 
waived. RECs should ensure that a clear and full justification for the 
proposed delay accompanies the research proposal. The individual 
circumstances of the patient must be carefully considered to prevent 
inadvertent violation of personal or cultural values. The REC may 
approve a delay in obtaining informed consent for emergency care 
research if the conditions specified above are met. Again, there is a 
presumption that the patient is alive.
Seeking consent after death
The term most commonly used in respect of consent from proxy 
decision-makers after death is ‘next of kin’. This terminology has its 
origin in Roman law and was used to apportion property between 
male relatives of a family. It became irrelevant in the UK when the 
Estates Act of 1925 was used for this purpose.[33] However, the term 
is widely used in the medical setting in SA and elsewhere. Some 
argue, using the definition of next of kin to include blood relatives 
only,[34] that it may be confusing in traditional extended families and 
communities where, contrary to conventional practice, the spouse 
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may not be regarded as ‘next of kin’. In SA, information disclosed 
after the death of a patient may be disclosed with the consent of the 
next of kin or the executors of the patient’s estate. There appears to 
be general agreement that the law in SA does not specify who next of 
kin is.[35] However, medical practitioners in SA rely on the National 
Health Act (NHA),[36] chapter 2, section 7, which specifies acceptable 
decision-makers in cases where a patient is unable to consent while 
alive. The hierarchy of surrogate decision-makers in the NHA is as 
follows: ‘the spouse or partner of the user [patient] or, in the absence 
of such spouse or partner, a parent, grandparent, an adult child or a 
brother or sister of the user [patient], in the specific order as listed’. As 
such, the spouse or partner is often consulted first even after death.
While respect for autonomy is narrowly interpreted in an 
individualistic society that defines a person as rational, autonomous, 
individual and separate from others, other notions of personhood 
exist, especially in some sub-Saharan African contexts including SA. 
More traditional notions of personhood are relational, communitarian 
and extended.[37] The family and community are regarded as the 
moral agent because the family is regarded as the most important 
aspect of identity. Given this cultural diversity in SA and its impact 
on healthcare and the lack of definition of next of kin in the law, it is 
important to explore the meaning of next of kin in different cultural 
contexts. This may have relevance after death too.
Collection of biological material  
from deceased persons
SA law recognises the importance of posthumous bodily integrity. 
In chapter 8 of the NHA,[36] section 62(2) specifies proxy consent, 
but the hierarchy after death differs from that during life. ‘Spouse, 
partner, major child, parent, guardian, major brother or sister’, in 
that order, may donate ‘specific tissue’ to an institution or person. [36] 
If these family members are not located, the Director-General of 
Health may authorise the use of the tissue, provided the ‘prescribed 
steps’ are taken to locate the person authorised to consent.[36] While 
these steps are not detailed in this section of the Act, other sections 
relating to donation of tissue for genetic testing, inter alia, describe 
the steps as follows: the Director-General of Health would need 
to obtain ‘the name, address and telephone number of the spouse, 
partner, major child, parent, guardian, major brother or major sister 
of the deceased person from: (i) any person working in the relevant 
hospital, institution or facility where the deceased died; or (ii) any 
person who visited the deceased before he or she died’.[36] Legal expert 
advice is ‘that these steps should also be followed for other donations 
of human tissue by the Director-General under the National Health 
Act’.[38] Clearly, this can be a lengthy process that will not be practical 
in a public health crisis.
In chapter 8, section 66, the NHA refers to postmortem examination 
of bodies. Here, either the patient may have given consent while alive 
or, in the absence of such consent, spouse, partner, major child, 
parent, guardian, major brother or sister – in that specific order. In 
the absence of such surrogates, section 67 refers to removal of tissue 
at postmortem examination and obtaining of tissue by institutions 
and persons. Subsection 1(a) indicates that the Minister of Health 
may authorise such removal of tissue for specific purposes including 
medical research, or a medical practitioner in charge of clinical 
services in a hospital (superintendent or chief executive officer, it 
is presumed) may authorise tissue removal for similar purposes, 
provided that the removal would not be contrary to ‘a direction given 
by the deceased before his or her death’[36] (NHA).
In terms of the Disaster Management Act,[2] COVID-19 has been 
declared a notifiable condition. Section 14 of the gazetted regula-
tions of chapter 3 of the NHA relating to the surveillance and control 
of notifiable medical conditions[39] specifies the following in regula-
tion 2: 
‘(a)  A case or carrier of a notifiable medical condition … or a 
medical condition deemed to be notifiable by the Minister, 
must subject himself or herself to further medical examination;
(b)  The medical examination referred to in sub-regulation (a) may 
include but is not limited to a clinical examination followed 
by the taking of biological specimens necessary for laboratory 
confirmation.’ This applies to a living person.
In the event of death, section 15 of the regulations indicates that 
‘the head of a provincial department must apply to a High Court 
for an order to conduct an autopsy on the body of a patient who 
has presumably died of a notifiable medical condition, in order 
to ascertain the exact cause of death, and only where this is in the 
interest of public health and is on special request by an interested 
person’.[39]
The 2015 NDoH research ethics guideline,[32] in respect of the 
collection of biological material for research after death, allows for 
proxy consent when a patient or donor is unable to consent (section 
3.3.6) or in the absence of a will or written statement of a deceased 
person. However, proxy consent in an ICU setting with a highly 
contagious and life-threatening disease has the potential to cause 
harm.
Considering potential harm
Due consideration should be given to potential harm that could 
stem directly from the informed consent process. Two scenarios are 
envisioned: either patients admitted to the ICU are asked to consent 
to the use of their biological samples should they die during their 
ICU stay, or the family are asked to provide proxy consent either 
prospectively or after the death of the patient. Both scenarios are 
problematic. In the first instance, the patient may be incapacitated 
by the underlying medical condition, severe pain or sedation, 
all of which may preclude obtaining truly informed consent.[40] 
Studies have estimated that only 10% of critically ill patients have 
sufficient decisional capacity,[41,42] while others have argued that 
it could be increased to roughly 50% if patients are assisted with 
communication. [43] Adequate communication may, however, be 
challenging in a setting where patients are infected with a highly 
transmissible pathogen, and staff are wearing PPE. Regardless, 
appropriate tools and adequate time and training would be needed 
to assess the decision-making capacity of such patients. This is not 
practical in the setting of contagion and acute respiratory distress. 
More importantly, the patient’s probable anxiety and fear in the 
face of possible and even imminent death when admitted with a 
dread disease may be aggravated by discussion of the post mortem 
collection of their samples.[40] It is also true that only 26 - 61.5% of 
the patients with COVID-19 admitted to the ICU will die, although 
it is currently not possible to predict death accurately in the absence 
of validated prognostic criteria.[44,45] The consent discussion will 
therefore not only be unnecessary, but also not hold out the potential 
for any benefit, for a large proportion of patients. So, while it is 
possible that some patients could have the capacity to consent, it 
can be argued that such a discussion could be harmful to patients in 
distress, especially in the ICU setting where family and counselling 
support will not be available.
The second scenario poses problems of obtaining consent from 
family members who are either distressed by ‘the emotional, 
psychological and logistic impact of the sudden hospitalisation’[40] 
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or in a state of bereavement after the death of a loved one. The 
psychological stress of having a family member in an ICU is known to 
result in anxiety (present in up to three-quarters of family members) 
and depression (in about a third),[46,47] learned helplessness,[48]  and 
acute post-traumatic stress disorder.[49] Distress and grief can distort 
cognition and impair family members’ capacity to critically evaluate 
the proposed research.[50] Some regulations therefore include the 
requirement that ‘a senior clinician supported by a staff member 
with appropriate skills in grief and bereavement counselling’, with the 
help of an interpreter when needed, obtain consent.[51] This approach 
has also been supported by researchers, based on the argument 
that bereaved family members should be formally recognised as a 
vulnerable group owing to diminished autonomy in the context of 
profound grief.[52] Moreover, concerns have been raised that family 
members may not be the best proxy decision-makers in such a 
setting. Studies comparing surrogate and delayed consent have 
reported discrepancies between the wishes of the surrogate and the 
patient of 16 - 20.3%, depending on the risk level of the study.[53,54]
Finally, the scientific integrity of the study could be harmed. 
Time constraints and workload pressures in a busy ICU may make 
obtaining adequately informed consent unfeasible.[40] For instance, 
a prospective observational study of research recruitment practices 
in 23 adult ICUs across Canada showed that consent was missed in 
28.8% of eligibility events and that operational reasons prevented 
consent in a further 28.5% of cases.[41] This non-inclusion of eligible 
patients could introduce bias in studies or limit the generalisability, 
and hence the scientific value, of the results, as well as delaying 
needed study conclusions by delaying recruitment.
Waiver of consent and deferred proxy 
consent for obtaining postmortem 
specimens?
Early publications relating to respiratory distress syndromes emerging 
from China, where the pandemic started, indicate that written 
informed consent was waived by the ethics regulatory authority,[18] 
or the authors do not mention whether consent was obtained at all, 
just that the study was conducted in keeping with the Declaration 
of Helsinki.[16] Article 30 of the Declaration discusses research with 
participants who are not able to provide informed consent. This 
includes unconscious patients. While obtaining consent from the 
legally authorised representative is advised, ‘if no such representative 
is available and if the research cannot be delayed, the study may 
proceed without informed consent provided that the specific reasons 
for involving subjects with a condition that renders them unable to 
give informed consent have been stated in the research protocol and 
the study has been approved by a research ethics committee. Consent 
to remain in the research must be obtained as soon as possible from 
the subject or a legally authorised representative.’[55]
Other international regulations and guidelines also allow for 
a waiver of consent for emergency research under very specific 
circumstances. For instance, the US Food and Drug Administration[31] 
in regulation 21 CFR 50.24 and the conforming amendments 
contained in 21 CFR Parts 56, 312, 314, 601, 812, and 814 provides 
a narrow exception to the requirement of obtaining informed 
consent from patients or legally authorised representatives prior to 
enrolment in emergency research. Pertinent conditions that have to 
be met include that the patient must be in a life-threatening situation, 
obtaining consent is not feasible, there is a chance of direct benefit 
for the participant, and the research cannot reasonably be carried out 
without the waiver.[56]
Assuming that the principles of beneficence and non-maleficence 
were met during life, and that the limited collection and storage of 
specimens obtained after death have the potential to directly inform 
the care of future patients, and where scientific reasons mandate 
that such collection should not be delayed (such as degradation of 
histology specimens), the question of a waiver of consent needs to 
be considered. Naturally, immediate or antemortem consent by a 
legal proxy would be ideal, unless this causes harm. However, in the 
context of COVID-19, the majority of clinical situations do not allow 
relatives to be present at the bedside or in hospitals. The delayed 
acquiring of consent would be likely to imply one of two situations. 
First, the collection of specimens should be delayed until proxy 
consent is obtained. If delays in obtaining consent are lengthy (e.g. 
more than a few hours), this situation could jeopardise the scientific 
quality of samples obtained, thereby negating the ethical validity of 
performing the study at all. Second, the specimens could be obtained 
at death, and delayed consent obtained at a later point by a proxy. This 
would preserve the scientific validity of the study, but acceptability to 
the proxy in certain instances may be unpalatable and is unknown. 
A possible mitigating strategy could be ensuring that delayed consent 
is conducted in a quiet and private environment where bereavement 
counselling and support are available.
Nevertheless, the ethical principles of autonomy, non-maleficence 
and justice once again come head to head: does collection of 
specimens after death for the ‘greater good’ of research to inform the 
treatment of future patients supersede the autonomy of the deceased? 
This is a difficult area, especially in the era of COVID-induced 
limitations of personal contact with relatives. Where collection of 
samples does not jeopardise the scientific process, or other unnamed 
ethical factors (e.g. delay in turning around a critical care bed), then 
delayed proxy consent would appear best. However, where timeous 
collection of specimens is required, obtaining immediate consent 
exposes the proxy to the trauma of having to simultaneously process 
news of death and consider the societal importance of obtaining 
such samples. On the other hand, a waiver of consent may appear 
to override the wishes of the proxy regarding the posthumous 
integrity of their relative. This is an unprecedented situation. Future 
patients need to be protected from unnecessary mortality by a better 
understanding of disease. Does this need supersede the individual 
rights of those unfortunate individuals who have succumbed to the 
infection?
Engaging communities as part of 
consent processes
In general, early and continuous community engagement (CE) is an 
integral part of regular research projects.[56] The FDA regulations only 
allow for a limited waiver of the need for consent when additional 
protections of the rights and welfare of participants are in place. 
These include consultation with representatives of the communities 
in which the clinical investigation will be conducted and from which 
participants will be drawn; public disclosure of the research, including 
potential risks and benefits; and public disclosure of the results and 
the demographics of the study after its completion.[31] CE is also 
promoted by the Nuffield Council on Bioethics, which has called for 
investment into such mechanisms in emergency research ‘to make 
them a reality’.[57] As part of the eight-step approach for CE described 
and strongly encouraged in the Tygerberg Research Ubuntu-inspired 
Community Engagement (TRUCE) Model, co-creation of knowledge 
production and co-development of CE material with communities 
are important.[58]
However, in emergency or urgent research conducted during 
COVID-19, when access to communities is limited during lockdown 
under the Disaster Management Act owing to the highly contagious 
nature of the disease, contacting community members, creating 
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community advisory boards and engaging early with communities 
is challenging. At best, CE can be attempted using social media and 
community newspapers in areas where these are still operating. 
For example, CE educational videos on research in general can be 
developed to assist communities to better understand the importance 
of research during this pandemic, including the possibility that 
samples of blood and tissue will be taken to learn more about 
COVID-19 and will be approved by an REC.
Conclusions
While a waiver of consent is reserved for extraordinary circumstances 
involving emergency research in global and SA research ethics 
guidance, none of these documents speaks to the unique scenario 
created by the current COVID-19 pandemic, where ICU research 
and histopathological diagnosis are critical to inform current and 
future care and are in the public interest. Given the challenges 
outlined above, it is clear that obtaining written informed consent in 
the context of critical care research during COVID-19, either before 
or after a patient has died, will not be feasible. Proxy consent when 
the family is contacted telephonically to inform them of the death of 
the patient would not only be impractical but, worse still, insensitive, 
especially if linguistic and cultural differences exist regarding end-of-
life beliefs and etiquette. This dilemma leaves researchers with little 
choice. Interpretation of the existing guidance in combination with 
SA legislation around notifiable diseases and obtaining biological 
samples for research after death provides some justification for a 
waiver of consent for the intended research, followed by deferred 
proxy consent at a later stage, as the most ethical route to follow.
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